bispecific antibodies

lung
Favicon Fierce Pharma

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

Combining the TROP2 ADC with Keytruda cut the risk of progression or death by 65% versus Keytruda alone in first-line, PD-L1-positive NSCLC.
Angus Liu May 21, 2026 5:00pm
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

UCB inks $2B Candid buyout to join Gilead in autoimmune field

May 4, 2026 7:46am
Stock market drop
Favicon Fierce Pharma

Summit shares tumble on interim PD-1/VEGF trial miss

May 1, 2026 10:56am
Wooden blocks with arrow and error icon Delays and disruptions stop the process critical error concept

BMS calls time on Zymeworks collab, ending work on bispecific

Apr 30, 2026 10:22am
Garbage truck picking up trash on suburban street

Janux axes solid tumor T-cell engager after poor ph. 1 showing

Apr 28, 2026 4:15am
Goal disorientation and lack of vision

Compass Therapeutics' stock heads south after bispecific OS miss

Apr 27, 2026 10:55am